Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Omega Protein Announces Second Quarter 2014 Financial Results

      Omega Protein Corporation Logo. (PRNewsFoto/Omega Protein Corporation) (PRNewsFoto/)

      News provided by

      Omega Protein Corporation

      Aug 06, 2014, 04:05 ET

      Share this article

      Share this article


      HOUSTON, Aug. 6, 2014 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME), a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products,  today reported financial results for the second quarter ended June 30, 2014.

      Second Quarter Highlights

      • Revenues:  $71.9 million for the quarter, compared to $41.8 million in the same period a year ago
      • Gross profit margin:  28.4% for the quarter, compared to 31.8% in the same period a year ago
      • Net income: $6.6 million, or $8.3 million excluding plant closure charges and gain on disposal of assets for the quarter, compared to $4.0 million in the same period a year ago
      • Earnings per diluted share: $0.31, or $0.38 excluding plant closure charges and gain on disposal of assets for the quarter, compared to $0.19 in the same period a year ago
      • Adjusted EBITDA:  $18.3 million for the quarter, compared to $11.8 million in the same period a year ago

      "We are pleased with our solid performance in the second quarter. Positive supply and demand fundamentals in our animal nutrition segment fueled our strong revenue and earnings performance," commented Bret Scholtes, Omega Protein's President and Chief Executive Officer.  "Even though we experienced short-term challenges in our human nutrition segment in the quarter, we believe our diversified nutritional business continues to evolve and provide us with the opportunity to take advantage of growing demand for quality health and wellness products."

      Second Quarter 2014 Results

      The Company's revenues increased 72% from $41.8 million in the same period last year to $71.9 million.  This increase was due to a $30.8 million increase in animal nutrition revenues, partially offset by a $0.7 million decrease in human nutrition revenues.  The increase in animal nutrition revenues was primarily due to increased sales volumes of 43% and 482% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish meal of 1%, partially offset by decreased sales prices of 37% for the Company's fish oil.  The decrease in fish oil sales prices was primarily due to a change in the product mix of higher priced refined and lower priced crude oils.  The decrease in human nutrition revenues was primarily due to lower Omega-3 tolling and other nutraceutical sales, partially offset by an increase in sales of protein products. The composition of revenue by nutritional product line for the second quarter of 2014 was 52% fish meal, 38% fish oil, 9% dietary supplements and food, and 1% fish solubles and other. 

      Second quarter of 2014 revenues increased 13% from $63.5 million in the first quarter of 2014 to $71.9 million.  This increase was due to an increase in animal nutrition revenues of $10.0 million, partially offset by a $1.6 million decrease in human nutrition revenues. The increase in animal nutrition revenues was primarily due increased sales volumes of 36% and 4% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish oil of 2%, partially offset by decreased sales prices of 4% for the Company's fish meal.  The decrease in human nutrition revenues was primarily due to lower Omega-3 and other nutraceutical sales.

      The Company reported gross profit of $20.4 million, or 28.4% as a percentage of revenues, for the second quarter of 2014, versus $13.3 million, or 31.8% as a percentage of revenues, in the second quarter of 2013. The decrease in gross profit as a percentage of revenues was due to reductions in both the animal and human nutrition segments.  Animal segment gross profit as a percentage of revenues declined from 33.9% to 30.3%, due in part to a higher cost per unit for current season production.  Human nutrition gross profit as a percentage of revenues decreased to 9.9% from 22.1% due primarily to higher raw material and other protein product costs and lower tolling revenues.

      Compared to the first quarter of 2014, second quarter gross profit decreased from $20.5 million, or 32.3% as a percentage of revenues, to $20.4 million, or 28.4% as a percentage of revenues.  Animal nutrition gross profit as a percentage of revenues decreased from 34.6% to 30.3%, primarily reflecting a higher cost per unit for current season production.  Human nutrition segment gross profit as a percentage of revenues decreased from 16.9% to 9.9% due largely to Omega-3 fish oil ingredients and tolling results.

      Selling, general and administrative expenses for the second quarter increased $0.5 million to $6.5 million compared to the second quarter of 2013, primarily as a result of higher employee related and professional services expenses.  Selling, general and administrative expenses increased $0.4 million from $6.1 million in the first quarter of 2014.

      In the fourth quarter of 2013, the Company closed its menhaden fish processing plant located in Cameron, Louisiana and re-deployed certain vessels from that facility to the Company's other Gulf Coast facilities located in Abbeville, Louisiana and Moss Point, Mississippi.  In conjunction with the closure, the Company incurred charges of $2.6 million in the second quarter of 2014 and $1.3 million in the first quarter of 2014.  

      The second quarter of 2014 effective tax rate was 36.9% compared to 34.7% in the second quarter of 2013 and 33.9% in the first quarter of 2014.

      Net income for the second quarter of 2014 was $6.6 million ($0.31 per diluted share) compared to $4.0 million ($0.19 per diluted share) in the same period last year and $8.0 million ($0.37 per diluted share) for the first quarter of 2014. Excluding plant closure charges and gain or loss on disposal of assets, net income for the second quarter of 2014 would have been $8.3 million ($0.38 per diluted share), compared to $4.0 million ($0.19 per diluted share) in the same period last year and $9.0 million ($0.42 per diluted share) for the first quarter of 2014.

      Adjusted EBITDA totaled $18.3 million for the second quarter of 2014, compared to $11.8 million for the same period last year and $19.1 million for the first quarter of 2014.

      Six Month 2014 Results

      Revenues in the first six months of 2014 increased 49% to $135.4 million compared to revenue of $90.7 million for the six months ended June 30, 2013. The increase in revenues was due to a $43.7 million increase in animal nutrition revenues and a $1.0 million increase in human nutrition revenues. The increase in animal nutrition revenues was primarily due to increased sales volumes of 15% and 187% for the Company's fish meal and fish oil, respectively, and increased sales prices for the Company's fish meal of 8%, partially offset by decreased sales prices of 12% for the Company's fish oil.  The increase in human nutrition revenues was due primarily to sales of protein products from Wisconsin Specialty Protein, a business acquired by the Company in the first quarter of 2013.

      The Company recorded gross profit of $40.9 million, or 30.2% as a percentage of revenues, for the first six months of 2014, versus gross profit of $25.4 million, or 28.0% as a percentage of revenues, for the first six months of 2013.  The increase in gross profit as a percentage of revenues was primarily due to the increase in animal segment sales prices, partially offset by a decrease in human nutrition gross profit as a percentage of revenues.

      The effective tax rate was 35.3% for the six months ended June 30, 2014 compared to 34.1% for the six months ended June 30, 2013.

      Net income for the six months ended June 30, 2014 was $14.6 million ($0.68 per diluted share) compared to $6.8 million ($0.33 per diluted share) for the same period last year.  Excluding the impact of the plant closure and loss on disposal of assets, net income for the six months ended June 30, 2014 would have been $17.3 million ($0.80 per diluted share) compared to $7.1 million ($0.34 per diluted share).

      Adjusted EBITDA totaled $37.4 million for six months ended June 30, 2014, an increase from $21.8 million for the same period last year.

      Balance Sheet

      The Company's June 30, 2014 cash balance increased $6.2 million from December 31, 2013 to $40.2 million.  Total debt decreased $1.9 million from December 31, 2013 to $22.4 million on June 30, 2014.  Stockholders' equity increased $17.0 million to $264.2 million as of June 30, 2014 compared to $247.2 million as of December 31, 2013. 

      Conference Call Information

      Omega Protein will host a conference call on its second quarter 2014 financial results at 8:30 a.m., Eastern Time, on Thursday, August 7, 2014. The Company's senior management team will be available to discuss recent financial results and current business trends as well as respond to questions.

      Please dial (877) 407-3982 domestically or (201) 493-6780 internationally to join the call. Interested parties may also listen to the webcast live over the Internet at www.omegaprotein.com.

      A webcast replay of the conference call will be available beginning shortly after the conclusion of the call at www.omegaprotein.com and will be available for 30 days. A telephonic replay of the conference call will be available through August 21, 2014. Domestic listeners can dial (877) 870-5176, and international listeners may dial (858) 384-5517. The replay access code is 13586946.

      About Omega Protein

      Omega Protein Corporation (NYSE: OME) is a century old nutritional company that develops, produces and delivers healthy products throughout the world to improve the nutritional integrity of functional foods, dietary supplements and animal feeds.  Omega Protein's mission is to help people lead healthier lives with better nutrition through sustainably sourced ingredients such as highly-refined omega-3 rich fish oil, specialty proteins and nutraceuticals.

      Forward Looking Statements

      SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: The statements contained in this press release that are not historical facts are forward-looking statements that involve a number of risks and uncertainties. Forward-looking information may be based on projections, predictions and estimates. Some statements in this press release may be forward-looking and use words like "may," "may not," "believes," "do not believe," "expects," "do not expect," "anticipates," "do not anticipate," "see," "do not see," "should," or other similar expressions. The actual results of future events described in any of these forward-looking statements could differ materially from those stated in the forward-looking statements. Important factors that could cause actual results to be materially different from those forward-looking statements include, among others: (1) the Company's ability to meet its raw material requirements through its annual menhaden harvest, which is subject to fluctuations due to natural conditions over which the Company has no control, such as varying fish population, fish oil yields, adverse weather conditions, natural and other disasters and disease; (2) the impact of laws and regulations that may be enacted that may restrict the Company's operations or the sale of the Company's products; (3) the impact of worldwide supply and demand relationships on prices for the Company's products; (4) the Company's expectations regarding demand and pricing for its products proving to be incorrect, and the effect of forward sales of products on the Company's financial results; (5) fluctuations in the Company's quarterly operating results due to the seasonality of the Company's business, estimates of standard cost for inventory and subsequent adjustments to such costs, and the Company's deferral of inventory sales based on worldwide prices for competing products; (6) the Company's ability to realize the anticipated benefits from its acquisitions in the human nutrition business, Nutegrity; (7) the Company's expectations regarding Nutegrity, its future prospects and the dietary supplement market or the human health and wellness segment generally, proving to be incorrect; (8) the cost of compliance with existing and future government regulations; (9) the impact of the Company's settlement with U.S. Attorney's Office on the Company's operations and financial results, including the impact of any failure to comply with the terms of the Company's probation or the limitations imposed on the Company's ability to secure government contracts or loans under the NFMS Title XI program; (10) the impact of the closure of the Company's Cameron, Louisiana processing plant on the Company's operations and financial results; (11) the cost of compliance or potential restrictions on sales caused by laws and regulations regarding fish meal or oil importation into foreign jurisdictions and (12) the effect of the previously reported July 28, 2014 explosion at the Company's Moss Point, Mississippi facility and subsequent temporary shut-down of that facility on the Company's business, results of operations or financial results.  Other factors are described in further detail in the Company's filings with the Securities and Exchange Commission, including its reports on Form 10-K, Form 10-Q and Form 8-K.

      OMEGA PROTEIN CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET

      (Dollars in thousands)




      June 30,

      2014


      December 31,

      2013

      ASSETS







       Current assets:







                Cash and cash equivalents


      $

      40,214


      $

      34,059

                Receivables, net



      31,304



      21,140

                Inventories



      79,860



      94,339

                Deferred tax asset, net



      904



      1,062

                Prepaid expenses and other current assets



      5,582



      3,915








                      Total current assets



      157,864



      154,515

      Other assets, net



      2,815



      5,234

      Property, plant and equipment, net



      154,431



      144,113

      Goodwill



      19,600



      19,600

      Other intangible assets, net



      7,596



      7,932

                      Total assets


      $

      342,306


      $

      331,394






      LIABILITIES AND STOCKHOLDERS' EQUITY














      Current liabilities:







               Current maturities of long-term debt


      $

      2,564


      $

      3,112

               Accounts payable



      4,074



      5,380

               Accrued liabilities



      25,910



      29,145

                    Total current liabilities



      32,548



      37,637

      Long-term debt, net of current maturities



      19,827



      21,130

      Deferred tax liability, net



      20,375



      19,351

      Pension liabilities, net



      3,246



      4,117

      Other long-term liabilities



      2,142



      1,929

                      Total liabilities



      78,138



      84,164


      Commitments and contingencies







      Stockholders' equity:







              Preferred stock, $0.01 par value; 10,000,000 authorized shares; none issued                                     



      —



      —

              Common Stock, $0.01 par value; 80,000,000 authorized shares;

                21,099,066 and 20,804,189 shares issued and 21,094,443 and

                20,804,189 shares outstanding at June 30, 2014 and

                December 31, 2013, respectively



      205



      203

              Capital in excess of par value



      138,557



      136,428

              Retained earnings



      131,411



      116,807

              Treasury stock, at cost – 4,623 shares



      (57)



      —

              Accumulated other comprehensive loss



      (5,948)



      (6,208)

                      Total stockholders' equity



      264,168



      247,230

                          Total liabilities and stockholders' equity


      $

      342,306


      $

      331,394










      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

      (In thousands, except per share amounts)




      Three Months Ended


      Six Months Ended



      June 30,


      June 30,



      2014


      2013


      2014


      2013

      Revenues

      $

      71,913

      $

      41,777

      $

      135,413

      $

      90,700

      Cost of sales


      51,489


      28,494


      94,496


      65,320

      Gross profit


      20,424


      13,283


      40,917


      25,380










      Selling, general, and administrative expense


      6,526


      6,030


      12,619


      12,473

      Research and development expense


      544


      565


      1,028


      1,120

      Loss related to plant closure


      2,616


      —


      3,939


      —

      Loss (gain) on disposal of assets


      (14)


      (2)


      233


      374

      Operating income


      10,752


      6,690


      23,098


      11,413

      Interest income


      5


      2


      13


      10

      Interest expense


      (135)


      (481)


      (382)


      (873)

      Other expense, net


      (118)


      (98)


      (174)


      (181)

      Income before income taxes


      10,504


      6,113


      22,555


      10,369










      Provision for income taxes


      3,871


      2,123


      7,951


      3,534

      Net income


      6,633


      3,990


      14,604


      6,835










      Other comprehensive income (loss):









      Energy swap adjustment, net of tax benefit of $10, $195, $20 and $56, respectively


      (19)


      (363)


      (37)


      (106)

      Pension benefits adjustment, net of tax expense of

         $80, $135, $160 and $270, respectively


      148


      251


      297


      502

      Comprehensive income

      $

      6,762

      $

      3,878

      $

      14,864

      $

      7,231



      Basic earnings per share

      $

      0.32

      $

      0.20

      $

      0.70

      $

      0.34



      Weighted average common shares outstanding


      20,428


      19,779


      20,392


      19,623



      Diluted earnings per share

      $

      0.31

      $

      0.19

      $

      0.68

      $

      0.33


      Weighted average common shares and potential

        common share equivalents outstanding


      21,105


      20,581


      21,062


      20,399


                                                                                                                               

      OMEGA PROTEIN CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

      (Dollars in thousands)




      Six Months Ended
      June 30,



      2014


      2013

      Cash flows from operating activities:





             Net income

      $

      14,604

      $

      6,835

             Adjustments to reconcile net income to net

                cash provided by operating activities:





              Depreciation and amortization


      10,335


      10,253

              Loss on plant closure


      1,858


      —

              Loss (gain) on disposal of assets


      233


      374

              Provisions for losses on receivables


      24


      24

              Share based compensation


      944


      891

              Deferred income taxes


      1,110


      1,409

              Changes in assets and liabilities:





                       Receivables


      (10,188)


      (2,671)

                         Inventories


      14,271


      (15,763)

                       Prepaid expenses and other current assets


      (1,724)


      (1,515)

                       Other assets


      1,679


      5,874

                       Accounts payable


      (1,306)


      (301)

                       Accrued liabilities


      (1,718)


      (2,536)

                       Pension liability, net


      (482)


      (246)

                       Other long term liabilities


      (2)


      30

                               Net cash provided by operating

                                   activities


      29,736


      2,658

      Cash flows from investing activities:





              Proceeds from disposition of assets


      193


      161

              Acquisition of Wisconsin Specialty Protein, net of

                  cash acquired


      —


      (26,779)

              Capital expenditures


      (23,268)


      (12,897)

                               Net cash used in investing activities


      (23,075)


      (39,515)

      Cash flows from financing activities:





              Principal payments of long-term debt


      (1,851)


      (1,569)

              Principal payments of capital lease obligation


      —


      (309)

              Purchase treasury stock at cost


      (57)


      —

              Proceeds from stock options exercised


      946


      3,048

              Excess tax benefit of stock options exercised


      456


      1,147

                               Net cash provided by (used in) financing

                                   activities


      (506)


      2,317

      Net increase (decrease) in cash and cash equivalents


      6,155


      (34,540)

      Cash and cash equivalents at beginning of year


      34,059


      55,998

      Cash and cash equivalents at end of period

      $

      40,214

      $

      21,458


      The tables below present information about reported segments for the quarters ended June 30, 2014 and 2013 (in thousands): 

      June 30, 2014


      Animal
      Nutrition


      Human
      Nutrition


      Unallocated


      Total

      Revenue (1)           


      $  65,264


      $    6,649


        $        ―


      $   71,913

      Cost of sales        


      45,501


      5,988


                  ―


      51,489

      Gross profit          


      19,763


      661


                  ―


      20,424

      Selling, general and administrative expenses

        (including research and development)          


      636


      2,067


      4,367


      7,070

      Loss related to plant closure             


      2,616


                ―


                  ―


      2,616

      Other (gains) and losses    


      (14)


                ―


                   ―


      (14)

      Operating income


      $    16,525


      $   (1,406)


      $     (4,367)


      $   10,752

      Depreciation and amortization          


      $      4,374


      $        699


      $            45


      $     5,118

      Identifiable assets               


      $ 224,416


      $  76,734


      $    41,156


      $ 342,306

      Capital expenditures           


      $      5,761


      $    4,692


        $           ―


      $   10,453

      (1)

      Excludes revenue from internal customers of $0.7 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      June 30, 2013


      Animal
      Nutrition


      Human
      Nutrition (
      2)


      Unallocated


      Total

      Revenue (3)           


      $    34,453


      $    7,324


        $        ―


      $    41,777

      Cost of sales        


      22,786


      5,708


                  ―


      28,494

      Gross profit          


      11,667


      1,616


                  ―


      13,283

      Selling, general and administrative expenses

        (including research and development)          


      662


      1,861


      4,072


      6,595

      Other (gains) and losses    


      (2)


                ―


                  ―


      (2)

      Operating income


      $    11,007


      $     (245)


      $    (4,072)


      $     6,690

      Depreciation and amortization          


      $      4,472


      $       632


      $         172


      $      5,276

      Identifiable assets               


      $ 227,462


      $ 57,861


      $   23,002


      $ 308,325

      Capital expenditures           


      $      5,741


      $       324


      $         119


      $      6,184

      (2)

      Includes revenues and related expenses for Wisconsin Specialty Protein ("WSP").



      (3)

      Excludes revenue from internal customers of $0.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      The tables below present information about reported segments for the six months ended June 30, 2014 and 2013 (in thousands).

      June 30, 2014


      Animal
      Nutrition


      Human
      Nutrition


      Unallocated


      Total

      Revenue(4)


      $ 120,534


      $  14,879


        $        ―


      $ 135,413

      Cost of sales


      81,668


      12,828


                  ―


      94,496

      Gross profit


      38,866


      2,051


                  ―


      40,917

      Selling, general and administrative expenses

        (including research and development)


      1,189


      3,988


      8,470


      13,647

      Loss related to plant closure


      3,939


                  ―


                  ―


      3,939

      Other (gains) and losses


      42


      191


                  ―


      233

      Operating income (loss)


      $    33,696


      $  (2,128)


      $   (8,470)


      $   23,098

      Depreciation and amortization


      $      8,742


      $   1,400


      $         193


      $   10,335

      Identifiable assets


      $ 224,416


      $ 76,734


      $   41,156


      $ 342,306

      Capital expenditures


      $   10,358


      $ 12,901


      $             9


      $   23,268

      (4)

      Excludes revenue from internal customers of $1.4 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      June 30, 2013


      Animal
      Nutrition


      Human
      Nutrition
      (5)


      Unallocated


      Total

      Revenue(6)


      $   76,790


      $  13,910


        $        ―


      $   90,700

      Cost of sales


      53,880


      11,440


                  ―


      65,320

      Gross profit


      22,910


      2,470


                  ―


      25,380

      Selling, general and administrative expenses

        (including research and development)


      1,290


      3,157


      9,146


      13,593

      Other (gains) and losses


      374


                ―


                  ―


      374

      Operating income (loss)


      $    21,246


      $      (687)


      $    (9,146)


      $   11,413

      Depreciation and amortization


      $      8,821


      $    1,070


      $         362


      $   10,253

      Identifiable assets


      $ 227,462


      $ 57,861


      $   23,002


      $ 308,325

      Capital expenditures


      $   12,046


      $       613


      $        238


      $   12,897

      (5)

      Includes revenues and related expenses for WSP from February 27, 2013 through June 30, 2013.



      (6)

      Excludes revenue from internal customers of $1.0 million for fish oil that was transferred from the animal nutrition segment to the human nutrition segment at cost.

      Adjusted EBITDA to Net Income Reconciliation
      The following table (in thousands) provides a reconciliation of Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2014, March 31, 2014 and June 30, 2013 and the six months ended June 30, 2014 and June 30, 2013:



      Three Months Ended




      June 30,

       2014


      March 31,
      2014


      June 30,

       2013


      Net Income

      $

      6,633

      $

      7,971

      $

      3,990


      Reconciling items:








           Interest expense


      105


      216


      451


           Income tax provision


      3,871


      4,080


      2,123


           Depreciation and amortization


      5,118


      5,217


      5,276


           Loss related to plant closure


      2,616


      1,323


      —


           Loss (gain) on disposal of assets


      (14)


      247


      (2)


      Adjusted EBITDA

      $

      18,329

      $

      19,054

      $

      11,838





      Six Months Ended





      June 30,

       2014


      June 30,

       2013


      Net Income


      $

      14,604

      $

      6,835


      Reconciling items:







         Interest expense



      321


      812


         Income tax provision



      7,951


      3,534


         Depreciation and amortization



      10,335


      10,253


         Loss (gain) on disposal of assets



      3,939


                     ―


         Net gain or loss on disposal of assets



      233


      374


      Adjusted EBITDA


      $

      37,383

      $

      21,808


      Adjusted EBITDA represents net income before interest expense, income tax, depreciation and amortization, loss related to plant closure and loss (gain) on disposal of assets. The Company has reported Adjusted EBITDA because it believes Adjusted EBITDA is a measure commonly reported and widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted EBITDA assists such investors in comparing a company's performance on a consistent basis. Adjusted EBITDA is not a calculation based on GAAP and should not be considered an alternative to net income in measuring our performance or used as an exclusive measure of cash flow because it does not consider the impact of working capital changes, capital expenditures, debt principal reductions and other sources and uses of cash which are disclosed in our consolidated statements of cash flows. Investors should carefully consider the specific items included in our computation of Adjusted EBITDA. While Adjusted EBITDA has been disclosed herein to permit a more complete comparative analysis of our operating performance relative to other companies, investors should be cautioned that Adjusted EBITDA as reported by us may not be comparable in all instances to Adjusted EBITDA as reported by us or by other companies. Adjusted EBITDA amounts may not be fully available for management's discretionary use, due to certain requirements to conserve funds for capital expenditures, debt service and other commitments, and therefore management relies primarily on our GAAP results. Adjusted EBITDA is not intended to represent net income as defined by GAAP and such information should not be considered as an alternative to net income, cash flow from operations or any other measure of performance prescribed by GAAP in the United States.

      Adjusted Net Income and Diluted Earnings Per Share to Net Income Reconciliation
      The following table (in thousands, except per share amounts) provides a reconciliation of Adjusted Net Income and Diluted Earnings Per Share, non-GAAP (Generally Accepted Accounting Principles) financial measures, to net income, the most directly comparable financial measure calculated and presented in accordance with GAAP, for the three months ended June 30, 2014, March 31, 2014 and June 30, 2013 and the six months ended June 30, 2014 and June 30, 2013:



      Three Months Ended




      June 30,

       2014


      March 31,
      2014


      June 30,

       2013


      Net Income

      $

      6,633

      $

      7,971

      $

      3,990


      Reconciling items:








           Income tax provision prior to adjustments


      3,871


      4,080


      2,123


           Loss related to plant closure


      2,616


      1,323


      —


           Loss (gain) on disposal of assets


      (14)


      247


      (2)


      Adjusted income before income taxes


      13,106


      13,621


      6,111


           Provision for income taxes after adjustments


      4,830


      4,612


      2,122


      Adjusted net income

      $

      8,276

      $

      9,009

      $

      3,989


      Adjusted diluted earnings per share

      $

      0.38

      $

      0.42

      $

      0.19





      Six Months Ended





      June 30,

       2014


      June 30,

       2013









      Net Income


      $

      14,604

      $

      6,835


      Reconciling items:







           Income tax provision prior to adjustments



      7,951


      3,534


           Loss related to plant closure



      3,939


                     ―


           Loss (gain) on disposal of assets



      233


      374


      Adjusted income before income taxes



      26,727


      10,743


           Provision for income taxes after adjustments



      9,422


      3,661


      Adjusted net income


      $

      17,305

      $

      7,082


      Adjusted diluted earnings per share


      $

      0.80

      $

      0.34


      Adjusted net income and Adjusted diluted earnings per share represent net income and diluted earnings per share without loss related to plant closure, loss (gain) on disposal of assets and taxes associated with these items. The Company has reported Adjusted net income and Adjusted diluted earnings per share because it believes these measures are widely used by investors as an indicator of a Company's operating performance. The Company believes Adjusted net income and Adjusted diluted earnings per share assist investors in comparing a company's performance on a consistent basis.  Adjusted net income and Adjusted diluted earnings per share are not calculations based on GAAP and should not be considered alternatives to net income or diluted earnings per share in measuring our performance. Investors should carefully consider the specific items included in our computation of Adjusted net income and Adjusted diluted earnings per share. While Adjusted net income and Adjusted diluted earnings per share has been disclosed herein to permit a more complete comparative analysis of our operating performance across time periods and relative to other companies, investors should be cautioned that these measures as reported by us may not be comparable in all instances to Adjusted net income and Adjusted diluted earnings per share as reported by us or by other companies. Adjusted net income and Adjusted diluted earnings per share are not intended to represent net income or diluted earnings per share as defined by GAAP and such information should not be considered as an alternative to net income, diluted earnings per share or any other measure of performance prescribed by GAAP in the United States.

      Logo - http://photos.prnewswire.com/prnh/20120717/NE41641LOGO

      SOURCE Omega Protein Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.